



*JFW*

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/627,556
	Filing Date	July 26, 2003
	First Named Inventor	LEDBETTER
	Art Unit	1645
	Examiner Name	To be Assigned
Total Number of Pages in This Submission	Attorney Docket Number	49076.000004.CIP2

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	SB/08, 7 cited references, and return postcard.
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	James W. Collett, Ph.D.
Signature	<i>James W. Collett</i>
Date	06/28/04

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Johann Lin		
Signature	<i>Johann Lin</i>	Date	06/28/04

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



49076.000004.CIP2  
U.S. PATENT

UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of	)	Group Art Unit: 1645
	)	
LEDBETTER	)	Examiner: To be Assigned
	)	
Serial No.: 10/627,556	)	Confirmation No.: 3297
	)	
Filed: July 26, 2003	)	Customer No.: 23464
	)	
For: BINDING CONSTRUCTS	)	
AND METHODS FOR USE	)	
THEREOF	)	

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)(3)

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In compliance with Applicant's duty under 37 C.F.R. § 1.97-98, the following information is brought to the attention of the Examiner. Please note, some of the references listed on the accompanying PTO/SB/08 form have come to Applicant's attention in a communication from a foreign patent office (International Search Report attached hereto, as well as a European Search Report) in a related foreign application. Applicant is submitting the International Search Report and the European Search Report from the International Searching Authorities for this purpose.


Copies of some of the documents listed on the Forms PTO-SB/08 were previously submitted in an IDS directed to the related application, U.S. Serial No. 10/053.530 and therefore hardcopies of those documents have not been included herewith. In accordance with 37 C.F.R. § 1.98(d) and MPEP 609(A)(2) duplicate copies need not be submitted and are not included herewith. The Examiner is requested to make these documents of record in the application.

The items identified in this Information Disclosure Statement may or may not be "material" pursuant to 37 C.F.R. § 1.56 and the submission thereof by Applicant shall not be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 C.F.R. § 1.97(h)), or even qualified as "prior art" under 35 U.S.C. § 102 with respect to this invention unless specifically designated by Applicant as such.

The Information Disclosure Statement is believed to be timely in that it is being submitted under 37 C.F.R. 1.97(b)(3) before the mailing of a first Office Action on the merits, whereby no petition or fee is required. However, if counsel for Applicant is in error in this regard, the Commissioner is requested to consider this a petition, and he is authorized to charge any required petition fee to counsel's Deposit Account No. 02-4553.

Respectfully submitted,

BUCHANAN INGERSOLL L.L.P.

By:   
James W. Collett, Ph.D.  
Reg. No. 46,636

One Oxford Centre  
301 Grant Street  
Pittsburgh, PA 15219-1410  
(O) (619) 578.5000  
(F) (619) 578.5940

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/207,655
				Filing Date	7/25/02
				First Named Inventor	Ledbetter
				Group Art Unit	1642
				Examiner Name	Helms
Sheet	1	of	13	Attorney Docket Number	49076.000004.CIP1

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	A.	4,704,692		Ladner	11/03/87
	B.	4,816,567		Cabilly et al.	03/28/89
	C.	4,906,562		Hellstrom et al	03/06/90
	D.	4,935,495		Hellstrom et a	06/19/90
	E.	4,946,778		Ladner et al.	08/07/90
	F.	5,091,177		Hellstrom et al	02/25/92
	G.	5,098,833		LASKY et al.	03/24/92
	H.	5,225,539		Winter	07/06/93
	I.	5,260,203		LADNER et al.	11/09/93
	J.	5,434,131		LINSLEY et al.	07/18/95
	K.	5,455,030		LADNER et al.	10/03/95
	L.	5,500,362		Robinson et al	03/19/96
	M.	5,521,288		LINSLEY et al.	05/28/96
	N.	5,530,101		Queen et al	06/25/96
	O.	5,580,756		LINSLEY et al.	12/03/96
	P.	5,585,089		Queen et al.	12/17/96
	Q.	5,597,707		Marken et al.	01/28/97
	R.	5,605,690		JACOBS et al.	02/25/97
	S.	5,637,481		LEDBETTER et al.	06/10/97
	T.	5,645,835		Fell, Jr. et al.	07/08/97
	U.	5,693,762		Queen et al.	12/02/97
	V.	5,709,859		ARUFFO et al.	01/20/98
	W.	5,714,147		CAPON et al.	02/03/98
	X.	5,770,197		LINSLEY et al.	06/23/98
	Y.	5,773,253		LINSLEY et al.	06/30/98
	Z.	5,795,572		Diegel et al.	08/18/98
	AA.	5,807,734		Diegel et al.	09/15/98
	BB.	5,844,095		LINSLEY et al.	12/01/98

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--


Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/207,655
				Filing Date	7/25/02
				First Named Inventor	Ledbetter
				Group Art Unit	1642
				Examiner Name	Helms
Sheet	2	of	13	Attorney Docket Number	49076.000004.CIP1

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	CC.	5,869,049		NOELLE et al.	02/9/99
	DD.	5,869,620		Whitlow et al.	02/09/99
	EE.	5,876,718		NOELLE et al.	03/02/99
	FF.	5,876,950		Siadak et al.	03/02/99
	GG.	5,888,773		Jost et al.	03/30/99
	HH.	5,892,019		Schlom ct al.	04/06/99
	II.	5,916,560		LARSEN et al.	06/29/99
	JJ.	6,087,329		ARMITAGE et al.	07/11/00
	KK.	6,090,914		LINSLEY et al.	07/18/00
	LL.	6,015,695		Casterman et al	01/18/00
	MM.	6,194,551 B1		IDUSOGIE et al.	02/27/01
	NN.	6,264,951 B1		ARMITAGE et al.	07/24/01
	OO.	6,312,692 B1		NOELLE et al.	11/06/01
	PP.	6,376,459 B1		ARUFFO et al.	04/23/02
	QQ.	6,384,198 B1		DIEGEL et al.	05/07/02
	RR.	6,410,319 B1		RAUBITSCHKE et al.	06/25/02
	SS.	6,444,792 B1		GRAY et al.	09/03/02
	TT.	6,472,510 B1		ARUFFO et al.	10/29/02
	UU.	6,623,940 B1		LEDBETTER et al.	09/23/03
	VV.	6,641,809 B1		LINSLEY et al.	11/04/03
	WW.	2003/0088074		Hamers et al	05/08/03
	XX.	2003/0219876 A1		LEDBETTER et al.	11/27/03
	YY.	2003/0219446 A1		LINSLEY et al.	11/27/03
	ZZ.	2003/0219436 A1		LEDBETTER et al.	11/27/03
	AAA.	2002/0155604 A1		LEDBETTER et al.	10/24/02
	BBB.	2004/0058445 A1		LEDBETTER et al.	03/25/04
	CCC.	2002/0039557 A1		WHITE	04/04/02
	DDD.	2002/0031510 A1		LARSEN et al.	03/14/02
	EEE.	2001/004135 A1		STAHL et al.	11/22/01


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/207,655
				Filing Date	7/25/02
				First Named Inventor	Ledbetter
				Group Art Unit	1642
				Examiner Name	Helms
Sheet	3	of	13	Attorney Docket Number	49076.000004.CIP1

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD- YYYY	
		Office <sup>3</sup>	Kind Code <sup>5</sup> Number <sup>4</sup> (if known)				
	FFF.	WO	89/07142		Morrison et al	08/10/89	
	GGG.	WO	92/00092		BRISTOL-MYERS SQUIBB COMPANY	01/09/92	
	HHH.	WO	93/00431		BRISTOL-MYERS SQUIBB COMPANY	01/07/93	
	III.	WO	94/04678		Casterman et al	03/03/94	
	JJJ.	WO	94/25591		Hamers et al	11/10/94	
	KKK.	WO	96/34103		Hamers et al	10/31/96	
	LLL.	WO	99/42077		XCYTE THERAPIES INC.	08/26/99	
	MMM.	EP	0 555 880 A2		BRISTOL-MYERS SQUIBB COMPANY	08/18/93	
	NNN.	EP	0 757 099 A2		BRISTOL-MYERS SQUIBB COMPANY	07/21/95	
	OOO.	EP	0 682 039 A1		BRISTOL-MYERS SQUIBB COMPANY	11/15/95	
	PPP.	EP	1 186 300 A1		BRISTOL-MYERS SQUIBB COMPANY	03/13/02	


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/207,655
				Filing Date	7/25/02
				First Named Inventor	Ledbetter
				Group Art Unit	1642
				Examiner Name	Helms
Sheet	4	of	13	Attorney Docket Number	49076.000004.CIP1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	QQQ.	AICHER, et al., "Characterization of Human Inducible Costimulator Ligand Expression and Function", The Journal of Immunology, 2000, 164: 4689-4696		
	RRR.	Batra et al., "Single-Chain Immunotoxins at the Human Transferrin ReceptorContaining Pseudomonas Exotoxin A or Diphtheria Toxin: Anti-TFR(Fv)-PE40 and DT388-Anti-TFR(Fv)," Molecular and Cellular Biology; 11(4):2200-2205, April 1991.		
	SSS.	Beiske et al., "Triggering of Neoplastic B Cells Via Surface IgM and the Cell Surface Antigens CD20 and CDw40. Responses Differ from Normal Blood B Cells and are Restricted to Certain Morphologic Subsets," Int. J. Cancer 42:521-528, 1988.		
	TTT.	BREKKE et al., "The Structural Requirements for Complement Activation by IgG: Does It Hinge on the Hinge?", Immunol. Today 16:85-90 (1995)		
	UUU.	Brown et al., "Treatment of B-Cell Lymphomas With Anti-idiotypic Antibodies Alone and in Combination With Alpha Interferon," Blood 73(3):651-661, February 15, 1989.		
	VVV.	BURKE et al., "Radioimmunotherapy for Acute Leukemia", Cancer Control, 9:106-113 (2002)		
	WWW.	CARTER, "Improving the Efficacy of Antibody-Based Cancer", Nature, November 2001, Volume 1, 118-129		
	XXX.	Chaudhary et al., "A recombinant immunotoxin consisting of two antibody variable domains, fused to Pseudomonas exotoxin," Nature 339:394-397, June 1, 1989.		


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Please type a plus sign (+) inside this box -



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/207,655
				Filing Date	7/25/02
				First Named Inventor	Ledbetter
				Group Art Unit	1642
				Examiner Name	Helms
Sheet	5	of	13	Attorney Docket Number	49076.000004.CIP1

	YYY.	Clark et al., "Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50," Proc. Natl. Acad. Sci. USA 83:4494-4498, June 1986.	
	ZZZ.	CLARK et al., "Structure, Function, and Genetics of Human B Cell-Associated Surface Molecules", Advances in Cancer Research, Vol. 52, 81-149	
	AAAA.	COLOMA, et al., "The Hinge as a Spacer Contributes to Covalent Assembly and Is Required for Function of IgG", J. Immunol. 158(2):733-40	
	BBBB.	DAMLE, et al., "Direct helper T cell-induced B cell differentiation involves interaction between T cell antigen CD28 and B cell activation antigen B7	
	CCCC.	DAVIES, et al., "'Camelising' Human Antibody Fragments: NMR Studies on VH Domains," FEBS Letters 339 (1994) 285-290	
	DDDD.	Davis et al., High Level Expression in Chinese Hamster Ovary Cells of Soluble Forms of CD4 T Lymphocyte Glycoprotein Including Glycosylation Variants," The Journal of Biological Chemistry 265(18):10410-10418, June 25, 1990.	
	EEEE.	DESMYTER et al., "Crystal structure of a camel single-domain V <sub>H</sub> antibody fragment in complex with lysozyme", Nature Structural Biology, Volume 3, Number 9, September 1996, 803-811	
	FFFF.	DIETSCH et al., "Bispecific receptor globulins, novel tools for the study of cellular interactions", Journal of Immunological Methods, 162 (1993) 123-132	
	GGGG.	DIETSCH et al., "Coengagement of CD2 with LFA-1 or VLA-4 by bispecific ligand fusion proteins primes T cells to respond more effectively to T cell receptor-dependent signals, Journal of Leukocyte Biology, Volume 56, October 1994, 444-452	
	HHHH.	Dillman et al., "Continuous Infusion of T 101 Monoclonal Antibody in Chronic Lymphocytic Leukemia and Cutaneous T-Cell Lymphoma, Journal of Biological Response Modifiers 5(5):394-410, 1986.	
	IIII.	DORAI, et al., "Role of InteFHeavy and Light Chain Disulfide Bonds in the Effector Functions of Human Immunoglobulin IgG1", Mol. Immunology 29:1487-1491 (1992).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



Please type a plus sign (+) inside this box



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/207,655
				Filing Date	7/25/02
				First Named Inventor	Ledbetter
				Group Art Unit	1642
				Examiner Name	Helms
Sheet	6	of	13	Attorney Docket Number	49076.000004.CIP1

	JJJJ.	DUNCAN, et al., "The Binding Site for Clq on IgG", Nature, 322:738-740 (1988)	
	KKKK.	DURIE et al., "Prevention of Collagen-Induced Arthritis with an Antibody to gp39, the Ligand for CD40", Science, Vol. 261, September 3, 1993, 1328-1330	
	LLLL.	Einfeld et al., "Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains," EMBO Journal 7:711-717, 1988.	
	MMMM.	FELL et al., "Genetic Construction and Characterization of a Fusion Protein Consisting of a Chimeric F (ab') with Specificity for Carcinomas and Human IL-2", The Journal of Immunology, Vol. 146, 2446-2452, No. 7, April 1, 1991	
	NNNN.	FILPULA et al., "Single-chain Fv designs for protein, cell and gene therapeutics" Exp. Opin. Ther. Patents (1999) 9 (3):231-245	
	OOOO.	Funakoshi et al., "Differential In Vitro and In Vivo Antitumor Effects Mediated by Anti CD40 and Anti-CD20 Monoclonal Antibodies Against Human B-Cell Lymphomas," Journal of Immunotherapy 19(2):93-101, 1996.	
	PPPP.	Funakoshi et al., "Inhibition of Human B-Cell Lymphoma Growth by CD40 Stimulation," Blood 83(10):2787-2794, May 15, 1994.	
	QQQQ.	Genbank Accession No. L07414, April 27, 1993.	
	RRRR.	Genbank Accession No. M62541, July 26, 1993.	
	SSSS.	Genbank Accession No. M62542, April 27, 1993.	
	TTTT.	Genbank Accession No. M83312, September 23, 1996.	
	UUUU.	Genbank Accession No. M84371, July 17, 1995.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Please type a plus sign (+) inside this box →

JUL 02 2004

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/207,655
				Filing Date	7/25/02
				First Named Inventor	Ledbetter
				Group Art Unit	1642
				Examiner Name	Helms
Sheet	7	of	13	Attorney Docket Number	49076.000004.CIP1

VVVV.	Genbank Accession No. U15637, March 8, 2002.	
WWWW.	Genbank Accession No. X14046, September 12, 1993.	
XXXX.	Genbank Accession No. X53517, February 17, 1992.	
YYYY.	Genbank Accession No. X65453, April 26, 2001.	
ZZZZ.	Genbank Accession No. X67878, June 6, 1997.	
AAAAA.	Genbank Accession No. X96710, February 13, 1997.	
BBBBB.	Genbank Accession No. Y10507, September 4, 1997.	
CCCCC.	GILLIES, et al., "Antigen Binding and Biological Activities of Engineered Mutant Chimeric Antibodies with Human Tumor Specificities", Hum. Antibodies Hybridomas 1:47-54 (1990)	
DDDDD.	GILLILAND et al., "Rapid and Reliable Cloning of antibody Variable Regions and Generation of Recombinant Single Chain Antibody Fragments", Tissue Antigens 1996: 47: 1-20 (Denmark0	
EEEEEE.	Hamers-Casterman et al.; Naturally occurring antibodies devoid of light chains. Nature. 1993 Jun 3;363(6428):446-8.	
FFFFFF.	HAYDEN et al., "Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen", Tissue Antigens 1996: 48; 242-254	
GGGGG.	HAYDEN, et al., "Antibody Engineering," Curr. Opin. Immuno., 9:201-212 (1997)	


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/207,655
				Filing Date	7/25/02
				First Named Inventor	Ledbetter
				Group Art Unit	1642
				Examiner Name	Helms
Sheet	8	of	13	Attorney Docket Number	49076.000004.CIP1

	HHHHH.	HAYDEN, et al., "Single-chain Mono- and bispecific Antibody Derivatives With Novel Biological Properties and Antitumor Activity from a COS Cell Transient Expression System," Thera. Immuno., 1:3-15 (1994)	
	IIIII.	HEKMAN et al., "Initial experience with treatment of human B cell lymphoma with anti CD19 monoclonal antibody," Cancer Immunol Immunother. 32:364-372, 1991.	
	JJJJJ.	HOLLENBAUGH et al., "The Human T cell antigen gp39, a member of the TNF gene family, is ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity," EMBO Journal 11:4313-4321, 1992.	
	KKKKK.	HU, et al., "Minibody: A Novel Engineered Anti-Carcinoembryonic Antigen Antibody Fragment (Single-Chain Fv-CH3) Which Exhibits Rapid, High-Level Targeting of Xenografts," Cancer Res. 56(13):3055-3061 (1996) (abstract only)	
	LLLLL.	HUDSON, "Recombinant antibodies: a novel approach to cancer diagnosis and therapy", Exp. Opin. Invest. Drugs (2000) 9(6):1231-1242	
	MMMMM.	HUDSON, "Recombinant antibody fragments", Current Opinion in Biotechnology, 1998, 9:395-402	
	NNNNN.	HUSTON et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxigenin single-chain Fv analogue produced in Escherichia coli," Proc. Natl. Acad. Sci. USA 85:5879-5883, August 1988.	
	OOOOO.	ISENMAN, et al., "Correlation between the Exposure of Aromatic Chromophores ", Biochemistry 16:233-240 (1977)	
	PPPPP.	JOST et al., "Mammalian Expression and Secretion of Functional Single-chain Fv Molecules," The Journal of Biological Chemistry 269(42):26267-26273, October 21, 1994.	
	QQQQQ.	KAMINSKI et al., Radioimmunotherapy of B-Cell Lymphoma with [131] I Anti-B1 (Anti-CD20) Antibody, The New England Journal of Medicine 329(7):459-465, August 12, 1993	
	RRRRR.	KATO et al., "A conformational change in the Fc precludes the binding of two Fcy receptor molecules to one IgG," Immunol Today 21(7):310-312, July 2000.	


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>			
				Application Number		10/207,655	
				Filing Date		7/25/02	
				First Named Inventor		Ledbetter	
				Group Art Unit		1642	
				Examiner Name		Helms	
Sheet	9	of	13	Attorney Docket Number		49076.000004.CIP1	

	SSSSS.	KLEIN, et al., "Expression of Biological Effector Functions by Immunoglobulin G Molecules Lacking the Hinge Region", Proc. Natl. Acad. Sci. USA 78:524-528 (1981)	
	TTTTT.	KOOLWIJK et al., "Interaction Between Hybrid Mouse Monoclonal Antibodies and the Human High-Affinity IgG FcR, huFcTRI, on U937," The Journal of Immunology 143(5):1656-1662 1989.	
	UUUUU.	KORTT, et al., "Dimeric and Trimeric Antibodies: High Avidity scFvs for Cancer Targeting," Biomole. Eng., 18:95-108 (2001)	
	VVVVV.	LASVELD et al., Treatment of low-grade non-Hodgkin s lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD 19," Cancer Immunol. Immunother: 40:37-47, 1995.	
	WWWWW.	LEDBETTER et al., "Augmentation of Normal and Malignant B Cell Proliferation by Monoclonal Antibody to the B Cell-Specific Antigen BP50 (CDW40)," The Journal of Immunology 138(3):788-794, February 1, 1987.	
	XXXXX.	LEE et al., "Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions", Molecular Immunology 36 (1999) 61-71	
	YYYYY.	LI, et al., "Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification and effect on tumor growth", Cancer Immunol. Immunother (2000) 49:243-252	
	ZZZZZ.	LIU et al., "Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity," The Journal of Immunology 139(10):3521-3526, November 15, 1987.	
	AAAAAA.	LIU, et al., "Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 With Potent Fc-Dependent Biological Activity," J. Immunol. 139(10):3521-3526 (1987)	
	BBBBBB.	MALONEY et al., "IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma," Blood 90(6):2188-2195, September 15, 1997.	
	CCCCCC.	MALONEY et al., "IDEC-C2B8: Results of a Phase I Multiple-Dose Trial in Patients With Relapsed Non-Hodgkin's Lymphoma, Journal of Clinical Oncology 15(10):3266-3274, October 1997.	


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/207,655
				Filing Date	7/25/02
				First Named Inventor	Ledbetter
				Group Art Unit	1642
				Examiner Name	Helms
Sheet	10	of	13	Attorney Docket Number	49076.000004.CIP1

	DDDDDD.	MCLAUGHLIN et al., "IDEC-C2B8 ANTI-CD20 Antibody: Final Report on a Phase III Pivotal Trial in Patients (PTS) With Relapsed Low-Grade or Follicular Lymphoma (LG/F NHL)," Blood 88(Abstract Suppl. 1):90a, Abstract 349, 1996.	
	EEEEEE.	MICHAELSEN, et al., "Antibody Dependent Cell-Mediated Cytotoxicity Induced by Chimeric Mouse-Human IgG Subclasses ...", Mol Immunol. 29:319-326 (1992)	
	FFFFFF.	MICHAELSEN, et al., "Enhancement of Complement Activation and Cytolysis of " Human IgG3 by Deletion of Hinge Exons"; Scand. J Immunol. 32:517-528; 1990.	
	GGGGGG.	MICHAELSEN, et al., "One Disulfide Bond in Front of the Second Heavy Chain Constant Region...", Proc. Natl. Acad. Sci. USA 91:9243-9247 (1994).	
	HHHHHH.	MULTANI et al., "Monoclonal Antibody-Based Therapeis for Hematologic Malignancies", Journal of Clinical Oncology, Vol. 16, No 11 (November), 1998: pp 3691-3710	
	IIIIII.	NIKULA, etal., "Impact of the High Tyrosine Fraction in Complementarity I Determining Regions: ...", Mol. Immunol. 32:865-872 (1995)	
	JJJJJJ.	PARK et al., "Generation and Characterization of a Novel Tetravalent Bispecific antibody that binds to hepatitis B virus surface antigens", Molecular Immunology 37 (2000) 11-23-1130	
	KKKKKK.	PAWSON et al., "Treatment of T-Cell Polymphocytic Leukemia With Human CD52 Antibody," Journal of Clinical Oncology 15(7):2667-2672, July 1997.	
	LLLLLL.	PRESS et al., " Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support." N Engl J Med. 1993 Oct 21;329(17):1219-24.	
	MMMMMM.	PRESS et al., "Monoclonal Antibody 1 F5 (Anti-CD20) Serotherapy of Human B Cell Lymphomas," Blood 69(2):584-591, February 1987.	
	NNNNNN.	RADAEV AND SUN, "Recognition of IgG by Fc <sub>γ</sub> Receptor," The Journal of Biological Chemistry 276(19):16478-16483, May 11, 2001.	


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Please type a plus sign (+) inside this box



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>			
				Application Number		10/207,655	
				Filing Date		7/25/02	
				First Named Inventor		Ledbetter	
				Group Art Unit		1642	
				Examiner Name		Helms	
Sheet	11	of	13	Attorney Docket Number		49076.000004.CIP1	

	OOOOOO.	RADAEV et al., "The Structure of a Human Type III Fcγ Receptor in Complex with Fc," The Journal of Biological Chemistry 276(19): 16469-16477, May 11, 2001.	
	PPPPPP.	REDPATH, et al., "The Influence of the Hinge Region Length in Binding of Human IgG to Human Fcγ Receptors", Hum. Immunol. 59:720-727 (1998)	
	QQQQQQ.	SCHEINBERG et al., "A Phase I Toxicity, Pharmacology, and Dosimetry Trial of Monoclonal Antibody OKB7 in Patients With Non-Hodgkin's Lymphoma: Effects of Tumor Burden and Antigen Expression," Journal of Clinical Oncology 8(5):792-803, May 1990.	
	RRRRRR.	SEGAL et al., "Introduction: bispecific antibodies", Journal of Immunological Methods, 248 (2001) 1-6	
	SSSSSS.	SENSEL et al., "Engineering Novel Antibody Molecules," Chemical Immunology 65:129-158 1997.	
	TTTTTT.	SHAN et al., "Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies," Blood 91(5):1644-1652, March 1, 1998.	
	UUUUUU.	SHAN et al., "Characterization of scFv-Ig Constructs Generated from the Anti-CD20 mAb 1F5 Using Linker Peptides of Varying Lengths," The Journal of Immunology 162(11):6589- 6595, June 1, 1999.	
	VVVVVV.	SHIN et al., "Genetically-Engineered Antibodies: Tools for the Study of Diverse Properties of the Antibody Molecule," Immunological Reviews 130:87-107, 1992.	
	WWWWWW.	SHIN et al., "Hybrid Antibodies," Intern. Rev. Immunol 10:177-186, 1993.	
	XXXXXX.	SHU et al., "Secretion of a single-gene-encoded immunoglobulin from myeloma cells", Proc. Natl. Acad. Sci. USA, Vol. 90, 7995-7999, September 1993	
	YYYYYY.	SMELLIE, et al., "Radioimmunotherapy of Breast Cancer Xenografts with Monoclonal Antibody ICR12 ...", Cancer Res. 55:5842s-5846s (1995)	
	ZZZZZZ.	SONDERMANN et al., " The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gamma RIII complex. Nature. 2000 Jul 20;406(6793):267-73.	


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>			
				Application Number		10/207,655	
				Filing Date		7/25/02	
				First Named Inventor		Ledbetter	
				Group Art Unit		1642	
				Examiner Name		Helms	
Sheet	12	of	13	Attorney Docket Number		49076.000004.CIP1	

	AAAAAAA.	SOURIAU et al., "Recombinant antibodies for cancer diagnosis and therapy", Expert Opin. Biol. Ther. (2003) 3(2):305-318	
	BBBBBBB.	SPORICI et al., "ICOS Ligand Costimulation Is Required for T-Cell Encephalitogenicity", Clinical Immunology, Vol. 100, No. 3, September, pp. 277-288, 2001	
	CCCCCCC.	TAN, et al, "Influence of the Hinge Region on Complement Activation, C1q Binding, and Segmental Flexibility in Chimeric Human Immunoglobulins", PNAS, USA, 87(1):162-6	
	DDDDDDD.	TAO, et al., "Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region", 1989, J. Immunol 143(8):2595-601)	
	EEEEEEE.	THOMMESEN, et al., "Lysine 322 in the Human IgG3 CH2 Domain Is Crucial for Antibody Dependent Complement Activation", Mol Immunol, 37:995-1004 (2000)	
	FFFFFFF.	TRAUNECKER et al., "Bispecific single chain molecules (Janusins) target cytotoxic lymphocyte on HIV infected cells," EMBO Journal 10:3655-3659, 1991.	
	GGGGGGG.	VAN DEN ABEELE, et al., "Antigen-Binding Site Protection During Radiolabeling Leads to a Higher Immunoreactive Fraction", J. Nucl. Med. 32:116-122 (1991)	
	HHHHHHH.	WALKER, et al., "Aglycosylation of Human IgG1 and IgG3 Monoclonal Antibodies Can Eliminate Recognition by Human Cells ...", 1989, Biochem. J. 259(2):347-53)	
	IIIIIII.	WHITE et al., Activation of dense human tonsillar B cells. Induction of c-myc gene expression via two distinct signal transduction pathways. J Immunol. 1991 Feb 1;146(3):846-53..	
	JJJJJJJ.	WU, et al., "Multimerization of a Chimeric Anti-CD20 Single-chain Fv-Fc Fusion Protein is Mediated Through Variable Domain Exchange," Protein Eng., 14(12):1025-1033 (2001)	
	KKKKKKK.	Ye z. et al; "Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat Med. 2002 Apr;8(4):343-8.	


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	
				10/207,655	
				<b>Filing Date</b>	
				7/25/02	
				<b>First Named Inventor</b>	
Ledbetter					
<b>Group Art Unit</b>					
1642					
<b>Examiner Name</b>					
Helms					
<b>Attorney Docket Number</b>					
49076.000004.CIP1					

	LLLLLLL.	YOKOTA et al "Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms" Cancer Res. 1992 52: 3402-3408.	
	MMMMMMM.	ZHOROV, et al., "Oxidative Iodination of Rabbit IgG: Localization of the Label in the Fc Fragment and Modification Effects", Biokhimiia 56:828-838 (1991)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--